Gastroesophageal Adenocarcinoma research hub

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

This study looks at a new combination of medicines (Zanidatamab, Pembrolizumab, and chemotherapy) for advanced stomach or food pipe cancer that has spread. It focuses on patients whose cancer has specific markers (HER2 and PD-L1 positive) and haven't had previous treatment for advanced disease.